Submitted:
10 September 2024
Posted:
10 September 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Design
2.2. Objectives
2.3. Inclusion Criteria
2.4. Exclusion Criteria
2.5. Methods
2.6. Technical Characteristics of the Three Devices
2.6. Ethics and Consent
2.7. Statistical Methods
3. Results
3.1.
3.2. Statistical Analyses
3.3. The Comparative Study of the Results of the Three Devices Using the MIRA© Algorithm
Statistical Study of the Results Obtained by AI Algorithm MIRA©
4. Discussion
5. Conclusions
6. Patents
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Simó R, Frontoni S. Neuropathic damage in the diabetic eye: clinical implications. Curr Opin Pharmacol. 2020 Dec; 55:1-7. [CrossRef]
- IDF Diabetes Atlas, 10th edn. Brussles, Belgium: International Diabetes Federation; 2021. Disponible en: https://www.diabetesatlas.org. (accessed 2024-07-24).
- Li JQ, Welchowski T, Schmid M, et al. Prevalence, incidence and future projection of diabetic eye disease in Europe: a systematic review and meta-analysis. Eur J Epidemiol. 2020 Jan;35(1):11-23. [CrossRef]
- Leasher JL, Bourne RR, Flaxman SR,et al; Vision Loss Expert Group of the Global Burden of Disease Study. Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010. Diabetes Care. 2016 Sep;39(9):1643-9. [CrossRef]
- Vision Loss Expert Group of the Global Burden of Disease Study; GBD 2019 Blindness and Vision Impairment Collaborators. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 2000 to 2020. Eye (Lond). 2024 Aug;38(11):2047-2057. [CrossRef]
- Weng CY, Maguire MG, Flaxel CJ, et al. Effectiveness of Conventional Digital Fundus Photography-Based Teleretinal Screening for Diabetic Retinopathy and Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. Ophthalmology. 2024 Aug;131(8):927-942. [CrossRef]
- Hainsworth DP, Bebu I, Aiello LP, et al; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care. 2019 May;42(5):875-882. [CrossRef]
- Romero-Aroca P, López-Galvez M, Martinez-Brocca MA, et al. Changes in the Epidemiology of Diabetic Retinopathy in Spain: A Systematic Review and Meta-Analysis. Healthcare (Basel). 2022 Jul 16;10(7):1318. [CrossRef]
- Grzybowski A, Rao DP, Brona P, et al. Diagnostic Accuracy of Automated Diabetic Retinopathy Image Assessment Softwares: IDx-DR and Medios Artificial Intelligence. Ophthalmic Res. 2023;66(1):1286-1292. [CrossRef]
- Vought R, Vought V, Shah M, et al. EyeArt artificial intelligence analysis of diabetic retinopathy in retinal screening events. Int Ophthalmol. 2023 Dec;43(12):4851-4859. [CrossRef]
- Baget-Bernaldiz M, Pedro RA, Santos-Blanco E, et al. Testing a Deep Learning Algorithm for Detection of Diabetic Retinopathy in a Spanish Diabetic Population and with MESSIDOR Database. Diagnostics (Basel). 2021 Jul 31;11(8):1385. [CrossRef]
- Romero-Aroca, P.; De La Riva-Fernandez, S.; Valls-Mateu, A.; et al. Changes observed in diabetic retinopathy. Eight years follow up of a Spanish population. Br. J. Ophthalmol. 2016, 100, 1366–1371.
- https://www.adcis.net/en/third-party/messidor/ (accessed 2024-07-24).
- RetinaReadRisk (RRR). Available at: https://www.iispv.cat/cas-dxit/retinareadrisk-rrr/ (Date Accessed: 2024-07-24).
- Romero-Aroca P, Verges-Puig R, de la Torre J, et al. Validation of a Deep Learning Algorithm for Diabetic Retinopathy. Telemed J E Health. 2020 Aug;26(8):1001-1009. [CrossRef]
- Wilkinson CP, Ferris F, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003, 110, 1677–1682.
- Shreffler J, Huecker MR. Diagnostic Testing Accuracy: Sensitivity, Specificity, Predictive Values and Likelihood Ratios.[Updated 2023 Mar 6]. InStatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2024. Available online: https://www.ncbi.nlm.nih.gov/books/NBK557491/ (accessed on 6 August 2024).
- Weng CY, Maguire MG, Flaxel CJ, et al. Effectiveness of Conventional Digital Fundus Photography-Based Teleretinal Screening for Diabetic Retinopathy and Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. Ophthalmology. 2024 Aug;131(8):927-942. [CrossRef]
- Grauslund, J. Diabetic retinopathy screening in the emerging era of artificial intelligence. Diabetologia. 2022 Sep;65(9):1415-1423. [CrossRef]
- Jacoba CMP, Doan D, Salongcay RP, et al. Performance of Automated Machine Learning for Diabetic Retinopathy Image Classification from Multi-field Handheld Retinal Images. Ophthalmol Retina. 2023 Aug;7(8):703-712. [CrossRef]
- Tan CH, Kyaw BM, Smith H, et al. Use of Smartphones to Detect Diabetic Retinopathy: Scoping Review and Meta-Analysis of Diagnostic Test Accuracy Studies. J Med Internet Res. 2020 May 15;22(5):e16658. [CrossRef]
- Palermo BJ, D'Amico SL, Kim BY, Brady CJ. Sensitivity and specificity of handheld fundus cameras for eye disease: A systematic review and pooled analysis. Surv Ophthalmol. 2022 Sep-Oct;67(5):1531-1539. [CrossRef]
- Kubin AM, Huhtinen P, Ohtonen P, et al. Comparison of 21 artificial intelligence algorithms in automated diabetic retinopathy screening using handheld fundus camera. Ann Med. 2024 Dec;56(1):2352018. [CrossRef]
- Jacoba CMP, Salongcay RP, Rageh AK, et al. Comparisons of Handheld Retinal Imaging with Optical Coherence Tomography for the Identification of Macular Pathology in Patients with Diabetes. Ophthalmic Res. 2023;66(1):903-912. [CrossRef]
- de Oliveira JAE, Nakayama LF, Zago Ribeiro L, et al. Clinical validation of a smartphone-based retinal camera for diabetic retinopathy screening. Acta Diabetol. 2023 Aug;60(8):1075-1081. [CrossRef]
- Salongcay RP, Aquino LAC, Alog GP, et al. Accuracy of Integrated Artificial Intelligence Grading Using Handheld Retinal Imaging in a Community Diabetic Eye Screening Program. Ophthalmol Sci. 2023 Dec 15;4(3):100457. [CrossRef]
- Kubin AM, Wirkkala J, Keskitalo A, et al. Handheld fundus camera performance, image quality and outcomes of diabetic retinopathy grading in a pilot screening study. Acta Ophthalmol. 2021 Dec;99(8):e1415-e1420. [CrossRef]
- Salongcay RP, Aquino LAC, Salva CMG, et al. Comparison of Handheld Retinal Imaging with ETDRS 7-Standard Field Photography for Diabetic Retinopathy and Diabetic Macular Edema. Ophthalmol Retina. 2022 Jul;6(7):548-556. [CrossRef]
- Jacoba CMP, Salongcay RP, Aquino LAC, et al. Comparisons of handheld retinal imaging devices with ultrawide field images for determining diabetic retinopathy severity. Acta Ophthalmol. 2023 Sep;101(6):670-678. [CrossRef]
| Level | Description |
|---|---|
| 0 | No retinopathy. |
| 1 | Mild-DR. Microaneurysms only. |
| 2 | Moderate-DR. More than just microaneurysms, but less than severe. |
| 3 |
|
| Levels of DME included in level 3 of current study | Mild DME: Some thickening of the retina or hard exudates at the posterior pole but distant from the centre of the macula. Moderate DME: thickening of the retina or hard exudates that approach the centre of the macula but do not involve the centre. Severe DME: thickening of the retina or hard exudates affecting the centre of the macula. |
| Vistaview | Aurora | Triton | |
|---|---|---|---|
| Field | 55⁰ | 50⁰ | 50⁰ |
| Pupil | 4 mm | 3.5 mm | 3.5 mm |
| Image Resolution | 28.4M pixels | 5 Mpixels | 5M pixels |
| Fountain | smartphone | Rechargeable lithium-ion battery | Mains |
| Mydriasis | Mydriatic | Non-mydriatic/mydriatic | Non-mydriatic / Mydriatic |
| Patients | Total retinographs | Patients who required mydriasis | Ungradable retinographs | ||
|---|---|---|---|---|---|
| Vistaview | 2130 | 4260 | All cases | 1192 / 27.98% | |
| Aurora | 2130 | 4260 | 1556 /73.05% | 340 / 7.98% | |
| Triton | 2130 | 4260 | 1536 / 71.11% | 20 / 0.93% | |
| No DR | Any DR | Mild-DR | Moderate- RD | Severe- RD | |
| Vistaview | 1962 / 69.83% | 168 /7.88% | 93/ 55.37%* | 57/ 33.92%* | 18/10.71%* |
| Aurora | 1948 / 83.91% | 186 / 8.54% | 109/ 58.39%* | 59/ 31.72%* | 18/ 9.89%* |
| Triton | 1948 / 90.03% | 188 / 8.82% | 110 / 58.51%* | 60 / 31.91%* | 18 / 9.57%* |
| TN | FN | TP | FP | S | SP | POS | NPV | ACC | F1score | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Any-DR | Vistaview | 1400 | 20 | 168 | 24 | 0.89 | 0.98 | 0.99 | 0.99 | 0.97 | 0.93 |
| Aurora | 1942 | 2 | 188 | 6 | 0.99 | 0.99 | 0.97 | 0.99 | 0.99 | 0.98 | |
| TN | FN | TP | FP | S | SP | POS | NPV | ACC | F1score | ||
| Mild-DR | Vistaview | 1404 | 17 | 93 | 20 | 0.85 | 0.99 | 0.82 | 0.99 | 0.93 | 0.91 |
| Aurora | 1942 | 1 | 109 | 8 | 0.99 | 0.99 | 0.93 | 0.99 | 0.99 | 0.95 |
| Classification of retinographs | ||||||
|---|---|---|---|---|---|---|
| Ungradable or MIRA | No DR | Any DR | Mild-DR | Moderate- DR | Severe- DR | |
| Vistaview | 1362 / 31.97% | 2330/54.46% | 284 /7.88% | 146/ 55.37% | 102/ 33.92% | 36/10.71% |
| Aurora | 342 / 8.02% | 3174/74.5% | 372 / 8.54% | 218/ 58.39% | 118/ 31.72% | 36/ 9.89% |
| Triton | 40 / 0.93% | 3468/81.4% | 376 / 8.82% | 220/ 58.52% | 120/ 31.91% | 36/9.57% |
| TN | FN | TP | FP | S | SP | POS | NPV | ACC | F1score | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Any-DR | Vistaview® | 2614 | 30 | 284 | 34 | 0.89 | 0.99 | 0.90 | 0.99 | 0.97 | 0.89 |
| Aurora® | 1201 | 2 | 130 | 1 | 0.99 | 0.99 | 0.98 | 0.99 | 0.99 | 0.98 | |
| Triton | 3842 | 2 | 376 | 2 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | |
| TN | FN | TP | FP | S | SP | POS | NPV | ACC | F1score | ||
| Mild-DR | Vistaview® | 2614 | 25 | 146 | 30 | 0.83 | 0.99 | 0.85 | 0.99 | 0.98 | 0.83 |
| Aurora® | 1201 | 2 | 130 | 1 | 0.99 | 0.99 | 0.98 | 0.99 | 0.99 | 0.98 | |
| Triton | 3842 | 2 | 220 | 2 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).